IBCN 2018: STAG2 Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle Invasive Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Alana Lelo a fifth-year Tumor Biology MD/ Ph.D. student discussed her team's STAG2 biomarker validation study using two independent cohorts of clinically-annotated papillary non muscle-invasive bladder cancer (NMIBC) tumors from the US and Europe.
IBCN 2018: Insights in the Role of Chemokines in Cancer Metastasization
Rotterdam, The Netherlands (UroToday.com) Marcus Thelan presented a lecture on chemokines and role in cancer metastatic disease. The chemokines are small peptide molecules of which 50 are known with 18 chemokine receptors. Tumors can evade the immune system by exploiting the chemokine system by downregulation, inhibition and/or promotion of chemokine system.
IBCN 2018: Consensus Molecular Classification of Muscle-Invasive Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Over the last decade, molecular subtyping efforts from several teams have led to distinct or partially overlapping molecular classifications of MIBC. Recent studies suggest that molecular subtyping on the basis of these classifications could be clinically useful to predict response to chemotherapy and/or immunotherapy.
IBCN 2018: Novel Immune Basal Subtypes to Predict Pathologic Response to Chemotherapy and Survival Benefit in Muscle-Invasive Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Woonyoung Choi, Ph.D. presented his team's work on immune basal subtypes in response to chemotherapy and survival. Using gene expression profiling, molecular subtypes are enriched with clinically actionable features in muscle-invasive bladder cancer (MIBC). To further explore the granular features of the subtypes, Dr. Choi and team extended their prior 3 subtypes (basal, luminal and p53-like) into 5 subtypes in TCGA MIBC dataset.
IBCN 2018: Combining DNA-Repair Gene Mutations and Molecular Subtyping for More Accurate Prediction of Outcome after Neoadjuvant
Rotterdam, The Netherlands (UroToday.com) Professor Roland Seiler presented a collaborative work combining DNA-repair gene mutations with molecular subtyping to predict outcomes following neoadjuvant chemotherapy. There remains a critical need to identify markers to predict response to cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) so that we can avoid NAC and proceed to timely surgery in likely non-responders.
IBCN 2018: Signature Immunohistochemical Classifier of Molecular Subtypes in Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Charles Guo presented their work regarding the identification of signature immunohistochemical markers that would permit simple and cost-effective classification of the disease in routine clinical practice. They analyzed genomic expression profiles of formalin-fixed paraffin embedded bladder cancer samples (n=74) to validate the expression signatures of luminal and basal subtypes and relate them to clinical data.
IBCN 2018: A Genomic Classifier for Identifying a Neuroendocrine-like Bladder Cancer Subtype
Rotterdam, The Netherlands (UroToday.com) Peter Black presented a genomic classifier developed which identified the neuroendocrine bladder cancer subtype. Neuroendocrine bladder carcinoma (NEBC) is a rare and aggressive variant. Molecular subtyping studies have found that 5-10% of muscle invasive bladder tumors have transcriptomic patterns consistent with NEBC in the absence of neuroendocrine (NE) histology.